Chester County News and Community Website
WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) said it achieved the primary and all secondary endpoints in a Phase 3 trial of QTORIN 3.9% rapamycin gel for microcystic lymphatic …
Palvella Reports Phase 3 Success for QTORIN in Rare Skin Disorder Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) said a newly published systematic review strengthens the scientific case for using topical statins to treat porokeratosis, a rare and progressive genetic …
Topical Statins Show Promise for Rare Skin Disease in New Review Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) is moving toward what could be a defining year, with a late-stage pipeline aimed at some of the most underserved rare skin …
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has named Vimal Patel, PharmD, as senior vice president of medical affairs, adding a seasoned dermatology and immunology executive as the company …
Palvella Taps Veteran Dermatology Executive to Steer Medical Affairs Push Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) said the U.S. Food and Drug Administration has granted Fast Track designation to QTORIN™ rapamycin for the treatment of angiokeratomas, a rare …
FDA Fast Track Puts Palvella’s Rare Skin Drug on a Faster Regulatory Path Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) reported positive topline results from a mid-stage clinical trial that positions its lead drug candidate as a potential first approved treatment for …
Rare Disease Breakthrough? Palvella Reports Strong Phase 2 Results Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) reported third-quarter results and detailed an intensifying slate of clinical milestones as its QTORIN platform advances across four rare dermatologic diseases — …
Palvella Races Toward Key 2026 Readouts as Rare-Disease Pipeline Expands Rapidly Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the development of QTORIN™ pitavastatin, a novel investigational therapy for disseminated superficial actinic porokeratosis (DSAP), a rare and progressive skin disease …
Palvella Unveils New Therapy Targeting Rare Premalignant Skin Disease DSAP Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it will report third-quarter 2025 financial results before markets open on Tuesday, November 11, 2025. Company leadership will host a live …
Palvella Therapeutics to Report Q3 Results, Highlight Progress in Rare Skin Disease Trials Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it has received the second year of funding under its U.S. Food and Drug Administration (FDA) Office of Orphan Products Development …
Palvella Therapeutics Receives Second Year of FDA Grant Funding for Phase 3 SELVA Trial Read More